Ontology highlight
ABSTRACT: Introduction
Reliable biomarkers of response to mTOR inhibition are yet to be identified. As mTOR is heavily implicated in cell-metabolism, we investigated the relation between BMI variation and outcomes in metastatic breast cancer (mBC) patients treated with everolimus.Results
we found a linear correlation between everolimus exposure duration and BMI/weight decrease. Patients exhibiting >2 kg weight loss or >3% BMI decrease from baseline at the end of treatment (EOT) had a statistically significant improvement in PFS. Interestingly, a similar BMI/weight decrease within the first 8 weeks of therapy identified patients at higher risk of progression.Patients and methods
we performed a retrospective analysis of patients enrolled in the BALLET trial who progressed during the study. Primary end-point was progression-free survival (PFS). Secondary end-point was the identification of other predictors of response.Conclusion
A >3% weight loss at EOT is associated with better outcome in mBC patients treated with everolimus. On the contrary, a significant early weight loss represents a predictor of poor survival and could therefore be used as an early negative prognostic marker. As PI3K-inhibition also converges onto mTOR, these findings might extend to patients treated with selective PI3K inhibitors and warrant further investigation.
SUBMITTER: Corona SP
PROVIDER: S-EPMC7289535 | biostudies-literature | 2020 Jun
REPOSITORIES: biostudies-literature
Corona Silvia P SP Giudici Fabiola F Jerusalem Guy G Ciruelos Eva E Strina Carla C Sirico Marianna M Bernocchi Ottavia O Milani Manuela M Dester Martina M Ziglioli Nicoletta N Barbieri Giuseppina G Cervoni Valeria V Montemurro Filippo F Generali Daniele D
Oncotarget 20200609 23
<h4>Introduction</h4>Reliable biomarkers of response to mTOR inhibition are yet to be identified. As mTOR is heavily implicated in cell-metabolism, we investigated the relation between BMI variation and outcomes in metastatic breast cancer (mBC) patients treated with everolimus.<h4>Results</h4>we found a linear correlation between everolimus exposure duration and BMI/weight decrease. Patients exhibiting >2 kg weight loss or >3% BMI decrease from baseline at the end of treatment (EOT) had a stati ...[more]